Unlock cells. Deliver innovation. PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies using our intracellular drug delivery shuttle. Our technology platform enables us to address the previously undruggable intracellular space with multiple payloads such as peptides, proteins, antibodies, and nucleic acids. As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in …

199 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel treatments at the forefront of oncology Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer …

115 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

INDIVIDUALIZED NK CELL THERAPIES XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer (NK) cell-based cancer therapies. The R&D pipeline targets areas of high unmet medical need within both hematological malignancies and solid tumors. The most advanced product candidate, evencaleucel, is being evaluated in a phase II clinical study in combination with the CD38 monoclonal antibody, isatuximab, as consolidation therapy following stem cell transplantation in newly diagnosed multiple myeloma patients. At the core of XNK is a committed and experienced team that includes world-renowned NK cell experts and pioneers in the field. The company has developed …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives. Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit. Kura developed and is commercializing KOMZIFTITM (ziftomenib), the …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The leading experts in cancer cell capture and analysis from liquid biopsies ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. …

277 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Let's Build Better Cells Together At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQureTM gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping …

334 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pushing the limits of conventional chemotherapy Doxanano is committed to pushing the limits of conventional chemotherapy for patients with solid tumors. Our goal is to significantly increase the selective delivery of chemotherapeutic agents into the tumor whilst dramatically limiting adverse effects on healthy organs. We specialize in harnessing the unique properties of our DXN polymersomes drug delivery platform in combination with the precision of radiotherapy.

77 similar entities Type: Startup Activities: deeptech Technologies: SaaS Synthetic Biology

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors. immunologie and oncologie

116 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Beyond Inhibition. Reprogramming Cancer Control. Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

www.xspraypharma.com Xspray Pharma (Nasdaq Stockholm: XSPRAY) aims to improve patients’ quality of life by developing and producing pharmaceuticals, based on world leading technology and deep industry expertise. Xspray Pharma uses its innovative, patented, and scalable technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The company has several product candidates in clinical development and a wide pipeline of potential candidates. The proven HyNap technology allows the company to gain entry before the secondary patents expire and can thereby benefit patients rapidly. Xspray Pharma's first product XS0004 dasatinib is pending FDA approval …

76 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

senolytic ADC StarkAge Therapeutics is a biotechnology company based in Lille, France, pioneering first-in-class senolytic antibody–drug conjugates (ADCs) to address age-related diseases, with an initial focus on oncology. The company’s lead program, STX-1, is a first-in-class ADC targeting DPP4, a highly selective marker of cellular senescence and a relevant tumor-associated antigen. STX-1 is currently progressing toward IND-enabling studies. oncology, ADC, Antibody Drug Conjugate, Senescence, and Senolytic ADC

77 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Breaking resistance barriers in oncology. ReACT Therapeutics is a French biotech company working to restore the effectiveness of cancer treatments and improve the quality of care provided to patients. Created in January 2023 in Grenoble, ReACT Therapeutics aims to develop a new class of molecules capable of blocking the phenomena of multi-resistance responsible for therapeutic failures. ➡️ Our mission: Work for and with patients to restore the effectiveness of their cancer treatments and improve the quality of their care. ➡️ Our goal: Develop a new class of molecules capable of blocking multi-resistance phenomena in oncology. The result of 15 years …

104 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and …

201 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We cultivate reciprocal relationships with anyone who crosses our path We are Napo Therapeutics: an European pharmaceutical company, a young start-up led by a team of experienced professionals. Our mission is to improve the quality of life of people suffering from rare diseases and pathologies with a strong unmet medical need through innovative solutions. Our name reflects our story: The Napo River crosses the territories of the Amazon where the Croton lechleri tree grows – the plant from which we extract the sap that contains a precious active ingredient. We are investigating an innovative and first-in-class drug thanks to the …

187 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com. Nuclear Medicine & Nuclear Industry, Biotechnology, Pharmaceutical, …

220 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer

181 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Creating transformative medicines for patients with cancer Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers. Biotech, Oncology, and Immuno-oncology

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell …

93 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

128 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

"Treating Tumors from the Inside" - Intra-tumoral delivery of oncology drugs OncoLize (NL) develops intra-tumoral drug depots to "Treat Tumors from the Inside". This means clinicians can inject and keep certain drugs where they are most effective: inside the tumor mass. Our patent protected ChemoGell(TM) platform is based on hydrogel technology, an awesome injectable drug depot platform developed at RCSI, Dublin by prof.dr. Helena Kelly and her team. We have an exclusive, world wide license for oncology. The base-patents have recently been granted in US, EU, China and Japan, with more in the pipeline. With the Gastro-Oncology team at Leiden …

199 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

we develop for patients Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university …

85 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Biopharmaceutical company focused cardiometabolic and inflammatory diseases Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.

111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Neem’s Hill is a holding company focused on investments and innovations in the medical device sector. Through its portfolio companies, it develops and commercializes patented Tumour Specific Electroporation (TSE) technology for cancer treatment. Today, the Group operates in both Human Care and Animal Care, with the ambition to improve clinical outcomes while reducing side effects through innovative, tissue-preserving cancer treatments. Cancer Treatments, Research, Clinical Development, Chemotherapy, and Immunotherapy

307 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your local champion and alternative partner Newbury Pharmaceuticals was founded in 2020 by Swedish Karl Karlsson. We are rapidly growing and offer a product portfolio of specialty pharma medicines with focus on the Scandinavian markets. The portfolio strategy includes niche and value-added small molecules, products based on peptide technology as well as biosimilars in a variety of therapeutic categories. The portfolio consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology representing more than 70 percent. The company was listed on Nasdaq First North, February 2022.

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Supercharging Immunotherapy At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV …

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

148 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

299 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

589 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Orexo is a pharma company dedicated to developing innovative medicines that save lives and address severe disease Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and pre-clinical development. The company collaborates with partners …

83 similar entities Type: SMB Activities: manufacturing deeptech healthtech Technologies: Synthetic Biology

Servier Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

215 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage medical device company committed to developing a ground-breaking platform technology to deliver anti-cancer drugs so they can act smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as …

192 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

634 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Pioneer of Click-to-Release chemistry; designing more effective and safer systemic therapies Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation in Marine-Derived Oncology Therapies Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other …

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis. Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown …

62 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. …

437 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

149 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology